Lacosamide (All indications) updated on 04-22-2025

Major congenital malformations

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S16583
R69647
Battino (Epilepsy), 2024 Major congenital malformations (MCMs) early pregnancy prospective cohort exposed to other treatment, sick Adjustment: No 0.52 [0.03;8.48] C 0/31   110/3,584 110 31
ref
S17213
R72104
The Australian Pregnancy Register of Antiepileptic Drugs (Mixed indications) (Controls exposed to LTG), 2024 Major congenital malformations at least 1st trimester prospective cohort exposed to other treatment, sick excluded Adjustment: No 6.27 [0.25;158.67] C
excluded (control group)
0/2   20/406 20 2
ref
S17214
R72106
The Australian Pregnancy Register of Antiepileptic Drugs (Mixed indications) (Controls unexposed, sick), 2024 Major congenital malformations at least 1st trimester prospective cohort unexposed, sick Adjustment: No 8.87 [0.33;236.26] C 0/2   7/207 7 2
ref
S17194
R72052
The Kerala Registry for Epilepsy and Pregnancy (Epilepsy) (Controls exposed to Lamotrigine), 2024 Major congenital malformations 1st trimester prospective cohort exposed to other treatment, sick excluded Adjustment: No 2.94 [0.11;81.30] C
excluded (control group)
0/6   1/50 1 6
ref
S17195
R72062
The Kerala Registry for Epilepsy and Pregnancy (Epilepsy) (Controls unexposed, sick), 2024 Major congenital malformations 1st trimester prospective cohort unexposed, sick Adjustment: No 1.78 [0.09;33.62] C 0/6   16/340 16 6
ref
S16193
R67086
The NAAED (Controls exposed to LTG) (Indications NOS), 2024 Major congenital malformations 1st trimester prospective cohort exposed to other treatment, sick excluded Adjustment: No 0.25 [0.02;4.05] C
excluded (control group)
0/93   52/2,461 52 93
ref
S16183
R67075
The NAAED (Controls unexposed, disease free) (Indications NOS), 2024 Major congenital malformations 1st trimester prospective cohort unexposed, disease free Adjustment: No 0.45 [0.03;7.61] C 0/93   15/1,311 15 93
ref
S17186
R72034
The UKIEPR (Epilepsy) (Controls exposed to Lamotrigine), 2024 Major malformations 1st trimester prospective cohort exposed to other treatment, sick excluded Adjustment: No 4.60 [0.24;86.58] C
excluded (control group)
0/5   49/2,098 49 5
ref
S17187
R72036
The UKIEPR (Epilepsy) (Controls unexposed, sick), 2024 Major malformations 1st trimester prospective cohort unexposed, sick Adjustment: No 4.34 [0.22;84.74] C 0/5   13/541 13 5
ref
S17217
R72112
The West China Registry (Epilepsy) (Controls exposed to LTG), 2024 Major congenital malformation during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick excluded Adjustment: No 8.33 [0.15;473.61] C
excluded (control group)
0/5   0/38 0 5
ref
S17218
R72114
The West China Registry (Epilepsy) (Controls unexposed, sick), 2024 Major congenital malformation during pregnancy (anytime or not specified) excluded prospective cohort unexposed, sick Adjustment: No 3.64 [0.18;73.84] C
excluded (exposition period)
0/5   7/253 7 5
ref
Total 5 studies 1.55 [0.41;5.79] 161 137
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Battino (Epilepsy), 2024Battino, 2024 1 0.52[0.03; 8.48]1103122%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: moderateROB mesure: moderateROB reporting: moderate The Australian Pregnancy Register of Antiepileptic Drugs (Mixed indications) (Controls unexposed, sick), 2024The Australian Pregnancy Regi..., 2024 2 8.87[0.33; 236.26]7216%ROB confusion: criticalROB selection: unclearROB classification: unclearROB missing: unclearROB mesure: criticalROB reporting: moderate The Kerala Registry for Epilepsy and Pregnancy (Epilepsy) (Controls unexposed, sick), 2024The Kerala Registry for Epile..., 2024 3 1.78[0.09; 33.62]16620%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate The NAAED (Controls unexposed, disease free) (Indications NOS), 2024The NAAED, 2024 4 0.45[0.03; 7.61]159322%ROB confusion: criticalROB selection: unclearROB classification: moderateROB missing: unclearROB mesure: criticalROB reporting: low The UKIEPR (Epilepsy) (Controls unexposed, sick), 2024The UKIEPR, 2024 5 4.34[0.22; 84.74]13520%ROB confusion: unclearROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Total (5 studies) I2 = 0% 1.55[0.41; 5.79]1611370.220.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Epilepsy; 2: Mixed indications) (Controls unexposed, sick; 3: Epilepsy) (Controls unexposed, sick; 4: Controls unexposed, disease free) (Indications NOS; 5: Epilepsy) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.55[0.41; 5.79]1611370%NABattino (Epilepsy), 2024 The Australian Pregnancy Register of Antiepileptic Drugs (Mixed indications) (Controls unexposed, sick), 2024 The Kerala Registry for Epilepsy and Pregnancy (Epilepsy) (Controls unexposed, sick), 2024 The NAAED (Controls unexposed, disease free) (Indications NOS), 2024 The UKIEPR (Epilepsy) (Controls unexposed, sick), 2024 5 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 0.45[0.03; 7.61]1593 -NAThe NAAED (Controls unexposed, disease free) (Indications NOS), 2024 1 unexposed, sickunexposed, sick 3.87[0.66; 22.55]36130%NAThe Australian Pregnancy Register of Antiepileptic Drugs (Mixed indications) (Controls unexposed, sick), 2024 The Kerala Registry for Epilepsy and Pregnancy (Epilepsy) (Controls unexposed, sick), 2024 The UKIEPR (Epilepsy) (Controls unexposed, sick), 2024 3 exposed to other treatment, sickexposed to other treatment, sick 0.52[0.03; 8.48]11031 -NABattino (Epilepsy), 2024 1 Tags Adjustment   - No  - No 1.55[0.41; 5.79]1611370%NABattino (Epilepsy), 2024 The Australian Pregnancy Register of Antiepileptic Drugs (Mixed indications) (Controls unexposed, sick), 2024 The Kerala Registry for Epilepsy and Pregnancy (Epilepsy) (Controls unexposed, sick), 2024 The NAAED (Controls unexposed, disease free) (Indications NOS), 2024 The UKIEPR (Epilepsy) (Controls unexposed, sick), 2024 5 All studiesAll studies 1.55[0.41; 5.79]1611370%NABattino (Epilepsy), 2024 The Australian Pregnancy Register of Antiepileptic Drugs (Mixed indications) (Controls unexposed, sick), 2024 The Kerala Registry for Epilepsy and Pregnancy (Epilepsy) (Controls unexposed, sick), 2024 The NAAED (Controls unexposed, disease free) (Indications NOS), 2024 The UKIEPR (Epilepsy) (Controls unexposed, sick), 2024 50.220.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-3.94.42.0100.000Battino (Epilepsy), 2024The Australian Pregnancy Register of Antiepileptic Drugs (Mixed indications) (Controls unexposed, sick), 2024The Kerala Registry for Epilepsy and Pregnancy (Epilepsy) (Controls unexposed, sick), 2024The NAAED (Controls unexposed, disease free) (Indications NOS), 2024The UKIEPR (Epilepsy) (Controls unexposed, sick), 2024

Asymetry test p-value = 0.0343 (by Egger's regression)

slope=-18.3265 (5.0817); intercept=12.4893 (3.3772); t=3.6981; p=0.0343

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 17213, 17194, 16193, 17186, 17217

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) Out of scale0.45[0.03; 7.61]1593 -NAThe NAAED (Controls unexposed, disease free) (Indications NOS), 2024 1 unexposed, sick controlsunexposed, sick controls 3.87[0.66; 22.55]36130%NAThe Australian Pregnancy Register of Antiepileptic Drugs (Mixed indications) (Controls unexposed, sick), 2024 The Kerala Registry for Epilepsy and Pregnancy (Epilepsy) (Controls unexposed, sick), 2024 The UKIEPR (Epilepsy) (Controls unexposed, sick), 2024 3 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.40[0.37; 5.33]2321370%NABattino (Epilepsy), 2024 The Australian Pregnancy Register of Antiepileptic Drugs (Mixed indications) (Controls exposed to LTG), 2024 The Kerala Registry for Epilepsy and Pregnancy (Epilepsy) (Controls exposed to Lamotrigine), 2024 The NAAED (Controls exposed to LTG) (Indications NOS), 2024 The UKIEPR (Epilepsy) (Controls exposed to Lamotrigine), 2024 50.510.01.0